Invasive breast cancer version 1.2016

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 3, 2016, Pages 324-354

  Gradishar, William J ^a   Anderson, Benjamin O ^b   Balassanian, Ron ^c   Blair, Sarah L ^d   Burstein, Harold J ^e   Cyr, Amy ^f   Elias, Anthony D ^g   Farrar, William B ^h   Forero, Andres ⁱ   Giordano, Sharon Hermes ^j   Goetz, Matthew ^k   Goldstein, Lori J ^l   Hudis, Clifford A ^m   Isakoff, Steven J ⁿ   Kelly Marcom, P ^o   Mayer, Ingrid A ^p   McCormick, Beryl ^q   Moran, Meena ^r   Patel, Sameer A ^r   Pierce, Lori J ^s   Reed, Elizabeth C ^t   Salerno, Kilian E ^u   Schwartzberg, Lee S ^b   Smith, Karen Lisa ^v   Smith, Mary Lou ^w   Soliman, Hatem ^x   Somlo, George ^y   Telli, Melinda ^z   Ward, John H ^aa   Shead, Dorothy A ^a   Kumar, Rashmi ^aa   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e Dana Farber/Brigham and Women's Cancer Center   (United States)

^f BARNES JEWISH HOSPITAL   (United States)

^g University of Colorado Cancer Center   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k MAYO CLINIC CANCER CENTER   (United States)

^l FOX CHASE CANCER CENTER   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

ⁿ DUKE CANCER INSTITUTE   (United States)

^o VANDERBILT INGRAM CANCER CENTER   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q YALE CANCER CENTER   (United States)

^r UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^s UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^t ROSWELL PARK CANCER INSTITUTE   (United States)

^u UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^v JOHNS HOPKINS UNIVERSITY   (United States)

^w Research Advocacy Network   (United States)

^x H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^y CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^z STANFORD CANCER INSTITUTE   (United States)

^aa UNIVERSITY OF UTAH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; AXILLARY LYMPH NODE; BIRTH CONTROL; BREAST CANCER; BREAST CARCINOMA; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; FERTILITY; HUMAN; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PREOPERATIVE CARE; REVIEW; SYSTEMIC THERAPY; TREATMENT PLANNING; TUMOR INVASION; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; FERTILITY PRESERVATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; UNITED STATES;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FERTILITY; FERTILITY PRESERVATION; HUMANS; MAMMAPLASTY; MASTECTOMY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; UNITED STATES;

EID: 84961577176     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0037     Document Type: Review

References (177)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Mohammad H, Forouzanfar KJF, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 2011;6736:61351-61352.
3. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-1846.
4. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151.
5. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678-687.
6. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235-237.
7. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992;65:252-254.
8. de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol 2011;9:93.
9. Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 2013;137:465-470.
10. Louie RJ, Tonneson JE, Gowarty M, et al. Complete blood counts, liver function tests, and chest x-rays as routine screening in early-stage breast cancer: value added or just cost? Breast Cancer Res Treat 2015;154:99-103.
11. Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005;23:1601-1602.
12. Gundry KR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park) 2005;19:159-169.
13. Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-Analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:3248-3258.
14. Weber JJ, Bellin LS, Milbourn DE, et al. Selective preoperative magnetic resonance imaging in women with breast cancer: no reduction in the reoperation rate. Arch Surg 2012;147:834-839.
15. Feigelson HS, James TA, Single RM, et al. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg 2013;216:966-975.
16. Katipamula R, Degnim AC, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 2009;27:4082-4088.
17. Sorbero ME, Dick AW, Beckjord EB, Ahrendt G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009;16:1597-1605.
18. Miller BT, Abbott AM, Tuttle TM. The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol 2012;19:536-540.
19. Peters NH, van Esser S, van den Bosch MA, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET-randomised controlled trial. Eur J Cancer 2011;47:879-886.
20. Turnbull LW, Brown SR, Olivier C, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). Health Technol Assess 2010;14:1-182.
21. Fischer U, Zachariae O, Baum F, et al. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14:1725-1731.
22. Solin LJ, Orel SG, Hwang WT, et al. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386-391.
23. Bleicher RJ, Ciocca RM, Egleston BL, et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 2009;209:180-187; quiz 294-185.
24. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: A randomised controlled trial. Lancet 2010;375:563-571.
25. White J, Morrow M, Moughan J, et al. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003;97:893-904.
26. Wilkinson NW, Shahryarinejad A, Winston JS, et al. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg 2003;196:38-43.
27. Baucom DH, Porter LS, Kirby JS, et al. Psychosocial issues confronting young women with breast cancer. Breast Dis 2005;23:103-113.
28. Dunn J, Steginga SK. Young womens experience of breast cancer: defining young and identifying concerns. Psychooncology 2000;9:137-146.
29. Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 2003;21:4184-4193.
30. Gorman JR, Bailey S, Pierce JP, Su HI. How do you feel about fertility and parenthood? The voices of young female cancer survivors. J Cancer Surviv 2012;6:200-209.
31. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review. J Natl Cancer Inst 2012;104:386-405.
32. Kranick JA, Schaefer C, Rowell S, et al. Is pregnancy after breast cancer safe? Breast J 2010;16:404-411.
33. Sukumvanich P, Case LD, Van Zee K, et al. Incidence and time course of bleeding after long-Term amenorrhea after breast cancer treatment: A prospective study. Cancer 2010;116:3102-3111.
34. Quinn GP, Block RG, Clayman ML, et al. If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients medical records. J Oncol Pract 2015;11:137-144.
35. Yee S, Abrol K, McDonald M, et al. Addressing oncofertility needs: views of female cancer patients in fertility preservation. J Psychosoc Oncol 2012;30:331-346.
36. Yeomanson DJ, Morgan S, Pacey AA. Discussing fertility preservation at the time of cancer diagnosis: dissatisfaction of young females. Pediatr Blood Cancer 2013;60:1996-2000.
37. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-2510.
38. Cruz MR, Prestes JC, Gimenes DL, Fanelli MF. Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: A systematic review. Fertil Steril 2010;94:138-143.
39. Dunn L, Fox KR. Techniques for fertility preservation in patients with breast cancer. Curr Opin Obstet Gynecol 2009;21:68-73.
40. Oktem O, Oktay K. Fertility preservation for breast cancer patients. Semin Reprod Med 2009;27:486-492.
41. Redig AJ, Brannigan R, Stryker SJ, et al. Incorporating fertility preservation into the care of young oncology patients. Cancer 2011;117:4-10.
42. Lee S, Ozkavukcu S, Heytens E, et al. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010;28:4683-4686.
43. Peate M, Meiser B, Friedlander M, et al. Its now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer-An Australian fertility decision aid collaborative group study. J Clin Oncol 2011;29:1670-1677.
44. Blumenfeld Z, Evron A. Preserving fertility when choosing chemotherapy regimens-The role of gonadotropin-releasing hormone agonists. Expert Opin Pharmacother 2015;16:1009-1020.
45. Del Mastro L, Lambertini M. Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy for fertility preservation: Toward the end of the debate? Oncologist 2015;20:1233-1235.
46. Lambertini M, Peccatori FA, Moore HC, Del Mastro L. Reply to the letter to the editor Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients? by Rodriguez-Wallberg et al [published online ahead of print December 8, 2015]. Ann Oncol, in press.
47. Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-932.
48. Moffat R, Guth U. Preserving fertility in patients undergoing treatment for breast cancer: current perspectives. Breast Cancer (Dove Med Press) 2014;6:93-101.
49. Oktay K, Turan V, Bedoschi G, et al. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 2015;33:2424-2429.
50. Baseline staging tests in primary breast cancer: Practice guideline report # 1-14: Members of the Breast Cancer Disease Site Group. Available at: http://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc1-14f.pdf Accessed: February 12, 2016.
51. Ravaioli A, Pasini G, Polselli A, et al. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 2002;72:53-60.
52. Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263-266.
53. Brothers JM, Kidwell KM, Brown RK, Henry NL. Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence. Breast Cancer Res Treat 2016;155:395-403.
54. Kumar R, Chauhan A, Zhuang H, et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267-274.
55. Podoloff DA, Advani RH, Allred C, et al. NCCN Task Force Report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5(Suppl 1):1-271.
56. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27(Suppl 1):S215-229.
57. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: A report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22:277-285.
58. Arriagada R, Le MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996;14:1558-1564.
59. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087-2106.
60. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-1241.
61. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-1232.
62. Early Breast Cancer Trialists Collaborative G, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-Analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 2011;378:1707-1716.
63. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014;32:1507-1515.
64. Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: A 25-year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719-725.
65. Komoike Y, Akiyama F, Iino Y, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 2006;106:35-41.
66. Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2007;101:51-57.
67. Golshan M, Miron A, Nixon AJ, et al. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006;192:58-62.
68. Kroman N, Holtveg H, Wohlfahrt J, et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688-693.
69. Blichert-Toft M, Nielsen M, During M, et al. Long-Term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 2008;47:672-681.
70. Litiere S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012;13:412-419.
71. Agarwal S, Pappas L, Neumayer L, et al. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg 2014;149:267-274.
72. Hwang ES, Lichtensztajn DY, Gomez SL, et al. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status. Cancer 2013;119:1402-1411.
73. Hartmann-Johnsen OJ, Karesen R, Schlichting E, Nygard JF. Survival is better after breast conserving therapy than mastectomy for early stage breast cancer: A registry-based follow-up study of Norwegian women Primary operated between 1998 and 2008. Ann Surg Oncol 2015;22:3836-3845.
74. Chatterjee A, Pyfer B, Czerniecki B, et al. Early postoperative outcomes in lumpectomy versus simple mastectomy. J Surg Res 2015;198:143-148.
75. Recht A. Contralateral prophylactic mastectomy: caveat emptor. J Clin Oncol 2009;27:1347-1349.
76. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010;102:401-409.
77. Jatoi I, Parsons HM. Contralateral prophylactic mastectomy and its association with reduced mortality: evidence for selection bias. Breast Cancer Res Treat 2014;148:389-396.
78. Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: A decision analysis. J Natl Cancer Inst 2014;106.
79. Fayanju OM, Stoll CR, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: A systematic review and meta-Analysis. Ann Surg 2014;260:1000-1010.
80. Rocha RD, Girardi AR, Pinto RR, de Freitas VA. Axillary ultrasound and fine-needle aspiration in preoperative staging of axillary lymph nodes in patients with invasive breast cancer. Radiol Bras 2015;48:345-352.
81. Bass SS, Lyman GH, McCann CR, et al. Lymphatic mapping and sentinel lymph node biopsy. Breast J 1999;5:288-295.
82. Cox CE. Lymphatic mapping in breast cancer: combination technique. Ann Surg Oncol 2001;8:67S-70S.
83. Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001;67:513-519.
84. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-A multicenter validation study. N Engl J Med 1998;339:941-946.
85. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-933.
86. Kuehn T, Vogl FD, Helms G, et al. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004;30:252-259.
87. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-7720.
88. McMasters KM, Giuliano AE, Ross MI, et al. Sentinel-lymph-node biopsy for breast cancer-not yet the standard of care. N Engl J Med 1998;339:990-995.
89. OHea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423-427.
90. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-553.
91. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst 2006;98:599-609.
92. Cox CE, Salud CJ, Cantor A, et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001;193:593-600.
93. Dupont E, Cox C, Shivers S, et al. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res 2001;97:92-96.
94. Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011;306:385-393.
95. Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: Assessment of an existing and a new predictive nomogram. Am J Surg 2005;190:543-550.
96. Houvenaeghel G, Nos C, Giard S, et al. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 2009;35:690-695.
97. Katz A, Smith BL, Golshan M, et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol 2008;26:2093-2098.
98. Kohrt HE, Olshen RA, Bermas HR, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 2008;8:66.
99. Scow JS, Degnim AC, Hoskin TL, et al. Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. Cancer 2009;115:4064-4070.
100. van la Parra RF, Ernst MF, Bevilacqua JL, et al. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol 2009;16:1128-1135.
101. Werkoff G, Lambaudie E, Fondrinier E, et al. Prospective multicenter comparison of models to predict four or more involved axillary lymph nodes in patients with breast cancer with one to three metastatic sentinel lymph nodes. J Clin Oncol 2009;27:5707-5712.
102. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426-432; discussion 432-423.
103. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011;305:569-575.
104. Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:1415-1418.
105. Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:2496-2501.
106. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-681.
107. Antonini N, Jones H, Horiot JC, et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007;82:265-271.
108. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378-1387.
109. Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008;26:2085-2092.
110. Mukesh MB, Barnett GC, Wilkinson JS, et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol 2013;31:4488-4495.
111. Mulliez T, Veldeman L, van Greveling A, et al. Hypofractionated whole breast irradiation for patients with large breasts: A randomized trial comparing prone and supine positions. Radiother Oncol 2013;108:203-208.
112. START Trialists Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet 2008;371:1098-1107.
113. START Trialists Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol 2008;9:331-341.
114. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-Term results of a randomised trial. Lancet Oncol 2006;7:467-471.
115. Whelan TJ, Pignol JP, Levine MN, et al. Long-Term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513-520.
116. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14:1086-1094.
117. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007;25:3259-3265.
118. Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997;15:963-968.
119. Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC boost vs. no boost trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 2000;55:219-232.
120. Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 2009;27:4939-4947.
121. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015;373:307-316.
122. Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015;373:317-327.
123. McCormick B. Partial-breast radiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. J Natl Compr Canc Netw 2005;3:301-307.
124. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009;74:987-1001.
125. Shaitelman SF, Vicini FA, Beitsch P, et al. Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: An analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer 2010;116:4677-4685.
126. Vicini F, Arthur D, Wazer D, et al. Limitations of the American Society of Therapeutic Radiology and Oncology Consensus Panel Guidelines on the use of accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2011;79:977-984.
127. Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005;23:1934-1940.
128. Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:1356-1361.
129. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971-977.
130. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-Term follow-up of CALGB 9343. J Clin Oncol 2013;31:2382-2387.
131. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963-970.
132. Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): A randomised controlled trial. Lancet Oncol 2015;16:266-273.
133. Hellman S. Stopping metastases at their source. N Engl J Med 1997;337:996-997.
134. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-955.
135. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:1641-1648.
136. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116-126.
137. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539-1569.
138. Early Breast Cancer Trialists Collaborative Group, McGale P, Taylor C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-Analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127-2135.
139. Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:4691-4699.
140. McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007;68:1004-1009.
141. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247-253.
142. Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-Term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:2268-2275.
143. Jagsi R, Raad RA, Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 2005;62:1035-1039.
144. Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women With T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011;29:2852-2858.
145. McLaughlin JM, Anderson RT, Ferketich AK, et al. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 2012;30:4493-4500.
146. Liu AS, Kao HK, Reish RG, et al. Postoperative complications in prosthesis-based breast reconstruction using acellular dermal matrix. Plast Reconstr Surg 2011;127:1755-1762.
147. McCarthy CM, Mehrara BJ, Riedel E, et al. Predicting complications following expander/implant breast reconstruction: An outcomes analysis based on preoperative clinical risk. Plast Reconstr Surg 2008;121:1886-1892.
148. Cowen D, Gross E, Rouannet P, et al. Immediate post-mastectomy breast reconstruction followed by radiotherapy: risk factors for complications. Breast Cancer Res Treat 2010;121:627-634.
149. Woerdeman LA, Hage JJ, Hofland MM, Rutgers EJ. A prospective assessment of surgical risk factors in 400 cases of skin-sparing mastectomy and immediate breast reconstruction with implants to establish selection criteria. Plast Reconstr Surg 2007;119:455-463.
150. Antony AK, McCarthy CM, Cordeiro PG, et al. Acellular human dermis implantation in 153 immediate two-stage tissue expander breast reconstructions: determining the incidence and significant predictors of complications. Plast Reconstr Surg 2010;125:1606-1614.
151. Ahmed S, Snelling A, Bains M, Whitworth IH. Breast reconstruction. BMJ 2005;330:943-948.
152. Edlich RF, Winters KL, Faulkner BC, et al. Advances in breast reconstruction after mastectomy. J Long Term Eff Med Implants 2005;15:197-207.
153. Pennington DG. Breast reconstruction after mastectomy: current state of the art. ANZ J Surg 2005;75:454-458.
154. Chang DW. Breast reconstruction with microvascular MS-TRAM and DIEP flaps. Arch Plast Surg 2012;39:3-10.
155. Kronowitz SJ, Robb GL. Radiation therapy and breast reconstruction: A critical review of the literature. Plast Reconstr Surg 2009;124:395-408.
156. Tran NV, Chang DW, Gupta A, et al. Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 2001;108:78-82.
157. Mehta VK, Goffinet D. Postmastectomy radiation therapy after TRAM flap breast reconstruction. Breast J 2004;10:118-122.
158. Berry T, Brooks S, Sydow N, et al. Complication rates of radiation on tissue expander and autologous tissue breast reconstruction. Ann Surg Oncol 2010;17(Suppl 3):202-210.
159. Francis SH, Ruberg RL, Stevenson KB, et al. Independent risk factors for infection in tissue expander breast reconstruction. Plast Reconstr Surg 2009;124:1790-1796.
160. Colwell AS, Damjanovic B, Zahedi B, et al. Retrospective review of 331 consecutive immediate single-stage implant reconstructions with acellular dermal matrix: indications, complications, trends, and costs. Plast Reconstr Surg 2011;128:1170-1178.
161. Garcia-Etienne CA, Cody Iii HS, Disa JJ, et al. Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. Breast J 2009;15:440-449.
162. Petit JY, Veronesi U, Orecchia R, et al. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European Institute of Oncology of Milan (EIO). Breast Cancer Res Treat 2009;117:333-338.
163. Yueh JH, Houlihan MJ, Slavin SA, et al. Nipple-sparing mastectomy: evaluation of patient satisfaction, aesthetic results, and sensation. Ann Plast Surg 2009;62:586-590.
164. Chung AP, Sacchini V. Nipple-sparing mastectomy: where are we now? Surg Oncol 2008;17:261-266.
165. Gerber B, Krause A, Dieterich M, et al. The oncological safety of skin sparing mastectomy with conservation of the nipple-Areola complex and autologous reconstruction: An extended follow-up study. Ann Surg 2009;249:461-468.
166. Mallon P, Feron JG, Couturaud B, et al. The role of nipple-sparing mastectomy in breast cancer: A comprehensive review of the literature. Plast Reconstr Surg 2013;131:969-984.
167. Piper M, Peled AW, Foster RD, et al. Total skin-sparing mastectomy: A systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg 2013;70:435-437.
168. Toth BA, Forley BG, Calabria R. Retrospective study of the skin-sparing mastectomy in breast reconstruction. Plast Reconstr Surg 1999;104:77-84.
169. Carlson GW, Styblo TM, Lyles RH, et al. The use of skin sparing mastectomy in the treatment of breast cancer: The Emory experience. Surg Oncol 2003;12:265-269.
170. Downes KJ, Glatt BS, Kanchwala SK, et al. Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer 2005;103:906-913.
171. Foster RD, Esserman LJ, Anthony JP, et al. Skin-sparing mastectomy and immediate breast reconstruction: A prospective cohort study for the treatment of advanced stages of breast carcinoma. Ann Surg Oncol 2002;9:462-466.
172. Medina-Franco H, Vasconez LO, Fix RJ, et al. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg 2002;235:814-819.
173. Newman LA, Kuerer HM, Hunt KK, et al. Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol 1998;5:620-626.
174. Clough KB, Kaufman GJ, Nos C, et al. Improving breast cancer surgery: A classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol 2010;17:1375-1391.
175. Anderson BO, Masetti R, Silverstein MJ. Oncoplastic approaches to partial mastectomy: An overview of volume-displacement techniques. Lancet Oncol 2005;6:145-157.
176. Huemer GM, Schrenk P, Moser F, et al. Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg 2007;120:390-398.
177. Kaur N, Petit JY, Rietjens M, et al. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol 2005;12:539-545.